{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:33:36Z","timestamp":1793424816127,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006225","name":"Oak Ridge Associated Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T12:09:14Z","timestamp":1557922154000},"page":"1524-1538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Therapeutic implications of nanomedicine for ocular drug delivery"],"prefix":"10.1016","volume":"24","author":[{"given":"Tuo","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Simmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-0771","authenticated-orcid":false,"given":"Qingguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.05.006_bib0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clindermatol.2014.10.006","article-title":"Human ocular anatomy","volume":"33","author":"Kels","year":"2015","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/eye.2008.10","article-title":"Short-term complications of intravitreal injections of triamcinolone and bevacizumab","volume":"22","author":"Jonas","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.05.006_bib0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2012.01.019","article-title":"Liposomes for intravitreal drug delivery: a state of the art","volume":"161","author":"Bochot","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.05.006_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.apsb.2016.09.001","article-title":"Nanotechnology-based strategies for treatment of ocular disease","volume":"7","author":"Weng","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drudis.2019.05.006_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2017.07.035","article-title":"Novel nanosystems for the treatment of ocular inflammation: current paradigms and future research directions","volume":"268","author":"Lalu","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijpharm.2016.07.031","article-title":"Dendrimers as a promising tool in ocular therapeutics: latest advances and perspectives","volume":"511","author":"Rodriguez Villanueva","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2019.05.006_bib0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics10010028","article-title":"Ocular drug delivery barriers\u2014role of nanocarriers in the treatment of anterior segment ocular diseases","volume":"10","author":"Bachu","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2019.05.006_bib0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.05.006_bib0055","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drudis.2019.05.006_bib0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4155\/cli.14.135","article-title":"Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence","volume":"5","author":"Ames","year":"2015","journal-title":"Clin. Invest."},{"key":"10.1016\/j.drudis.2019.05.006_bib0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jfo.2017.08.009","article-title":"[Prospective, monocentric, uncontrolled study of efficacy, tolerance and adherence of cyclosporin 0.1 % for severe dry eye syndrome]","volume":"41","author":"Boujnah","year":"2018","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","article-title":"Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa(R)) for dry eye disease","volume":"36","author":"Mandal","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0075","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S175065","article-title":"A Phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0080","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/ICO.0b013e318206caee","article-title":"The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy","volume":"30","author":"Su","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2019.05.006_bib0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2017.0052","article-title":"Relevance of lipid-based products in the management of dry eye disease","volume":"33","author":"Garrigue","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.05.006_bib0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijpharm.2012.08.016","article-title":"Cyclosporin nanosphere formulation for ophthalmic administration","volume":"437","author":"Khan","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2019.05.006_bib0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exer.2013.07.027","article-title":"Tear film mucins: front line defenders of the ocular surface: comparison with airway and gastrointestinal tract mucins","volume":"117","author":"Hodges","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.05.006_bib0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.05.006_bib0110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2013.05.035","article-title":"Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus","volume":"170","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0115","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of Surface Polyethylene Glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2019.05.006_bib0120","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/anie.201006849","article-title":"Biodegradable nanoparticles\u2009composed entirely of safe materials that rapidly penetrate human mucus","volume":"50","author":"Yang","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.drudis.2019.05.006_bib0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-014-0021-z","article-title":"Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation","volume":"3","author":"Schopf","year":"2014","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.drudis.2019.05.006_bib0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.4.3.11","article-title":"Topical ocular drug delivery to the back of the eye by mucus-penetrating particles","volume":"4","author":"Schopf","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0135","first-page":"668","article-title":"A comparative review on conventional and advanced ocular drug delivery formulations","volume":"2","author":"Rajasekaran","year":"2010","journal-title":"Int. J. Pharm. Tech. Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2019.03.023","article-title":"Depot formulations to sustain periocular drug delivery to the posterior eye segment","author":"Agban","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.05.006_bib0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.addr.2017.09.008","article-title":"Overcoming ocular drug delivery barriers through the use of physical forces","volume":"126","author":"Huang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.05.006_bib0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.1977.04450020112019","article-title":"Periocular injection of corticosteroids \u2013 experimental evaluation of its role in treatment of corneal inflammation","volume":"95","author":"Leibowitz","year":"1977","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0155","first-page":"297","article-title":"An autoradiographic study of the penetration of subconjunctivally injected hydrocortisone into the normal and inflamed rabbit eye","volume":"4","author":"McCartney","year":"1965","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0160","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/bjo.76.11.681","article-title":"Pharmacokinetics of ophthalmic corticosteroids","volume":"76","author":"McGhee","year":"1992","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0165","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1021\/mp2005164","article-title":"Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib","volume":"9","author":"Malik","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.05.006_bib0170","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.110.037408","article-title":"Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids","volume":"39","author":"Thakur","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2019.05.006_bib0175","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0180","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0002-9394(99)00129-4","article-title":"High concentration\u2009of dexamethasone in aqueous and vitreous after subconjunctival injection","volume":"128","author":"Weijtens","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0185","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/archopht.1969.00990010790006","article-title":"Increased intraocular pressure following subconjunctival corticosteroid administration","volume":"81","author":"Kalina","year":"1969","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0190","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ajo.2012.09.027","article-title":"Long-term rejection incidence and reversibility after penetrating and lamellar keratoplasty","volume":"155","author":"Guilbert","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0195","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0200","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1167\/iovs.06-0985","article-title":"A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection","volume":"48","author":"Lee","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.018","article-title":"Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis","volume":"296","author":"Luo","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2015.01.009","article-title":"Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats","volume":"201","author":"Pan","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0215","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/ICO.0b013e318197ef07","article-title":"Survey of steroid usage patterns during and after low-risk penetrating keratoplasty","volume":"28","author":"Price","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2019.05.006_bib0220","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajo.2007.03.028","article-title":"Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty","volume":"144","author":"Nguyen","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.nano.2019.01.001","article-title":"Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization","volume":"17","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.006_bib0230","first-page":"123","article-title":"Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye","volume":"7","author":"Natarajan","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2019.05.006_bib0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/nn4046024","article-title":"Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma","volume":"8","author":"Jayaganesh","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2019.05.006_bib0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024513","article-title":"Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye","volume":"6","author":"Natarajan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.006_bib0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2415-12-9","article-title":"A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 \u03bcg\/ml to latanoprost 50 \u03bcg\/ml (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension","volume":"12","author":"Eveleth","year":"2012","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-24545-2","article-title":"Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.05.006_bib0255","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/ICO.0b013e31823f8b40","article-title":"Activated macrophages induce neovascularization through upregulation of MMP-9 and VEGF in rat corneas","volume":"31","author":"Li","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2019.05.006_bib0260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","article-title":"Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation","volume":"125","author":"Soiberman","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.05.006_bib0265","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jtos.2018.05.004","article-title":"Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis","volume":"16","author":"Lin","year":"2018","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.drudis.2019.05.006_bib0270","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/bm101046d","article-title":"Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice","volume":"12","author":"Sadekar","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.drudis.2019.05.006_bib0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14712598.3.1.45","article-title":"Drug delivery to the retina: challenges and opportunities","volume":"3","author":"Duvvuri","year":"2003","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drudis.2019.05.006_bib0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13346-010-0009-8","article-title":"Intravitreal poly(l-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases","volume":"1","author":"Shelke","year":"2011","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","article-title":"Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo","volume":"167","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0290","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2015.01.030","article-title":"Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy","volume":"202","author":"Martens","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0295","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0300","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"The CATT Research Group","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.006_bib0305","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-9394(89)90866-0","article-title":"Ocular adverse reactions associated with adriamycin (doxorubicin)","volume":"108","author":"Curran","year":"1989","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0310","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jconrel.2013.10.008","article-title":"Sustained delivery of a HIF-1 antagonist for ocular neovascularization","volume":"172","author":"Iwase","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0315","unstructured":"McDonnell, P.J. et al. (2014) Sustained Delivery of Therapeutic Agents to an Eye Compartment. U.S. Patent No. 8889193 B2."},{"key":"10.1016\/j.drudis.2019.05.006_bib0320","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/193229680800200628","article-title":"Anti-inflammatory polymeric coatings for implantable biomaterials and devices","volume":"2","author":"Bridges","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0325","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.drudis.2019.05.006_bib0330","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2146\/ajhp120131","article-title":"Fenofibrate-associated nephrotoxicity: a review of current evidence","volume":"70","author":"Attridge","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.drudis.2019.05.006_bib0335","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.8b01319","article-title":"Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration","volume":"16","author":"Qiu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.05.006_bib0340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2019.05.006_bib0345","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo","volume":"22","author":"Takahashi","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.05.006_bib0350","unstructured":"Graybug Vision. Available at: https:\/\/graybug.com\/science\/."},{"key":"10.1016\/j.drudis.2019.05.006_bib0355","first-page":"4115","article-title":"Modifications of sunitinib-loaded GB-102 microparticles that lengthen drug release: 9-months ocular tolerability and PK in rabbit following IVT dosing","volume":"58","author":"Yang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0360","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/nnm.10.89","article-title":"Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration","volume":"5","author":"Dai","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.006_bib0365","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1167\/iovs.14-16250","article-title":"Systemic and intravitreal delivery of dendrimers to activated microglia macrophage in ischemia reperfusion mouse retina","volume":"56","author":"Kambhampati","year":"2015","journal-title":"Invest. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0370","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.biomaterials.2011.10.010","article-title":"Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration","volume":"33","author":"Iezzi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.05.006_bib0375","first-page":"1942","article-title":"Systemic dendrimer-based combination therapies for AMD","volume":"58","author":"Rangaramanujam","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0385","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/bjo.82.6.704","article-title":"Systemic corticosteroid therapy\u2014side effects and their management","volume":"82","author":"Stanbury","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0390","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1021\/ar2000315","article-title":"PRINT: a novel platform toward shape and size specific nanoparticle theranostics","volume":"44","author":"Perry","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0395","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2009.09.032","article-title":"The hydrogel template method for fabrication of homogeneous nano\/microparticles","volume":"141","author":"Acharya","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.006_bib0400","first-page":"5672","article-title":"Sustained release, biodegradable PEA implants for intravitreal delivery of the ROCK\/PKC inhibitor AR-13503","volume":"59","author":"Glendenning","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.006_bib0405","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.nano.2017.02.007","article-title":"Nano-ophthalmology: applications and considerations","volume":"13","author":"Kamaleddin","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.006_bib0410","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1021\/bc5006224","article-title":"The present and the future of degradable dendrimers and derivatives in theranostics","volume":"26","author":"Leiro","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.drudis.2019.05.006_bib0415","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.msec.2018.03.002","article-title":"Biodegradable dendrimers for drug delivery","volume":"90","author":"Huang","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.drudis.2019.05.006_bib0420","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"S. Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.05.006_bib0425","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/OED.S38028","article-title":"Intravitreal injection of Ozurdex\u00ae implant in patients with persistent diabetic macular edema, with six-month follow-up","volume":"8","author":"Pacella","year":"2016","journal-title":"Ophthalmol. Eye Dis."},{"key":"10.1016\/j.drudis.2019.05.006_bib0430","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/ijo.IJO_634_16","article-title":"Immortal ozurdex: a 10-month follow-up of an intralenticular implant","volume":"65","author":"Poornachandra","year":"2017","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.006_bib0435","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd3745","article-title":"Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:40:57Z","timestamp":1761223257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618304355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618304355"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.006","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic implications of nanomedicine for ocular drug delivery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}